Tag Archives: pink

Genetics

Genetics Discovery Reveals How Legumes Give Oxygen to Symbiotic Bacteria in Their Roots – SciTechDaily

Legume Root nodules colored pink by leghaemoglobin and caused by a symbiotic relationship between the plant and beneficial bacteria. Credit: John Innes Centre

Scientists discover the genetics inside legumes that control the production of an oxygen-carrying molecule, crucial to the plants close relationships with nitrogen-fixing bacteria.

The finding offers the potential to give other plants the ability to produce ammonia from bacteria reducing the need for the fossil fuel-dependent and polluting practice of applying synthetic fertilizer to crops.

The roots of legume plants are home to symbiotic bacteria. These bacteria can fix nitrogen from the air, turning it into ammonia, a key nutrient for plants.

In return, the plants house the bacteria in root nodules, providing sugars and oxygen. The amount of oxygen needs to be just right to support the symbiosis, the bacteria need oxygen to fuel their chemical reactions, but too much inhibits a key enzyme that turns nitrogen in the air into the ammonia that can be used by the plant.

The plants solution to this oxygen paradox of biological nitrogen fixation is a molecule called leghemoglobin. Like hemoglobin that carries oxygen in our blood, leghemoglobin binds to oxygen and is red; it gives legume nodules their pink color. Until now its been unclear how plants control how much of this molecule is produced.

The research team have identified two transcription factors that control how much leghemoglobin is made in legume nodules.

This gives a key insight into how legume plants create the microaerobic environment needed for nitrogen-fixation. This knowledge could be useful for improving nitrogen-fixation in legumes and would be essential for transfer of nodulation to non-legume crops, explains corresponding author Dr. Jeremy Murray, CEPAMS Group Leader.

Dr. Jeremy Murray continues, While many genes involved in other nodulation processes have been identified, this is the first breakthrough on the gene regulatory network involved directly in control of nitrogen fixation.

The research was carried out by a collaborative team, led by Dr. Suyu Jiang in Dr Jeremy Murrays group at theCAS-JIC Centre of Excellence for Plant and Microbial Science (CEPAMS), Centre for Excellence in Molecular Plant Sciences (CEMPS), Chinese Academy of Sciences, Shanghai, China, with collaboration from Dr. Pascal Gamas and Dr. Marie-Franoise Jardinaud at LIPME (Universit de Toulouse, France).

Using the model legume,Medicago truncatula, the research team looked at a family of proteins in plants which has several members with roles in nodulation. They looked at which proteins in this class are produced in symbiosis-housing nodules and found that there was two NIN and NLP2, and that when these are inactive, nitrogen fixation is reduced. This suggested that they are involved in nitrogen fixation.

To investigate further, they grew plants in an aeroponic system, without soil, to be able to look at the nodules, and found the plants lacking NIN and NLP2 were smaller in size and had smaller and less-pink nodules. On closer inspection, they had lower levels of leghemoglobin. Further experiments found that NIN and NLP2 directly activate the expression of leghemoglobin genes.

This research project was purely curiosity-driven, all we knew at the outset was that the transcription factor we were studying was highly and specifically expressed in nitrogen-fixing cells, we were initially not aware of any connection to leghemoglobins, reflects Dr. Murray.

The research has also given insights into the evolution of this important symbiosis. They found that other members of the transcription factors family regulate the production of non-symbiotic hemoglobins found in plants, which are involved in plants response to low oxygen levels.

Jeremy explains further, This was exciting because it suggests that these transcription factors and their hemoglobin targets were recruited to nodulation as modules to help improve energetics in nitrogen-fixing cells, giving a rare glimpse into how this symbiosis evolved.

Reference: NIN-like protein transcription factors regulate leghemoglobin genes in legume nodules 28 October 2021, Science.DOI: 10.1126/science.abg5945

Read more from the original source:
Genetics Discovery Reveals How Legumes Give Oxygen to Symbiotic Bacteria in Their Roots - SciTechDaily

Physiology

Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs – BioSpace

SCOTTSDALE, Ariz., June 3, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs. These Stage I programs will study how electro-modulation communicates to cells by modifying intracellular signaling events and altering physiological cellular response.

Electro-modulation therapies (electroceuticals) are conducted and widely applied in medicine today utilizing a variety of frequencies to reduce chronic pain. A front page TIME magazine article noted: "Electroceuticals "are the next wave of new treatments we will have to treat disease," says Kris Famm, president of Galvani Bioelectronics, a biotech collaboration between Glaxo-Smith-Kline and Google's Verily that is focused on developing electricity-based therapies (https://time.com/5709245/bioelectronic-medicine-treatments/). Going forward, researchers hope to learn how alternating electrical fields affect cell physiology and induce their effects.

The main challenge is to define specific electrical frequencies that alter cell physiology by modulating the body's cellular signaling network. Deciphering the impacts of alternating electrical fields on cell signaling will build a solid platform for the development of novel non-invasive technologies in medicine. Once this process is unlocked, leading bioelectronic producers such as Electromedical Technologies could develop new, highly effective, and application/condition-specific devices for broad consumer use.

Matthew Wolfson, Founder and CEO of Electromedical Technologies, noted, "Unraveling the codes of electro-modulation controlling cell behavior will be instrumental in developing effective and targeted applications of the next generation of bioelectronic devices. Thus, decoding the language of electro-modulation is a focus of our research team spearheaded by Professor Dos Sarbassov at Nazarbayev University. We are pleased to be working together on these promising studies that could have a favorable impact on human health using physics instead of drugs."

Dr. Sarbassov is a prominent expert in cell signaling, who received an intensive postdoctoral research training at MIT's Whitehead Institute for Biomedical Research and worked for many years as a Faculty Member of the Molecular and Cellular Oncology Department at MD Anderson Cancer Center. He joined Nazarbayev University in 2019 to contribute to a scientific development of the country of his origin. In 2020, Dr. Sarbassov became a Director of the National Laboratory Astana (NLA), a leading research organization at Nazarbayev University.

Dr. Dos Sarbassov commented, "Our work with the Electromedical Technologies is a great collaborative effort of an academic institution with private industry. This joint focus is on advancing technology by understanding the mechanisms of electrical communication with cell physiology. Our primary initial goal is to study and determine how cells react to alternating electrical fields by analyzing their effects on cell signaling and by translating how they lead to distinct responses of cells and tissues."

Matthew Wolfson commented further, "We seek to utilize the deciphering of the mechanisms of electrical signaling on cells in an effort to provide a solid foundation in our development of effective treatments of inflammation, neurodegenerative disorders and opioid addiction. With the new agreement and program parameters in place, the Company and the University look forward to commencing the IDE (Investigational Device Exemption) process leading to a submission with the FDA."

About Nazarbayev University:

Nazarbayev University (NU), established on the initiative of the first President of the Republic of Kazakhstan in 2010, is the country's flagship academic institution with aspirations to become a global-level research university. This is the first university in Kazakhstan which is guided by the principles of autonomy and academic freedom. Located in the capital of Kazakhstan, NU is a research university with growing international renown combining education, research and innovation on a state of the art 21st-century campus. NU scholars conduct research in many fields, and seek to expand human knowledge through innovation, analysis, and collaboration. Within ten years since its inception, NU has become a leading research university in Kazakhstan. NU research is supported by the government of the Republic of Kazakhstan, local and international organizations, and is carried out in the Schools, Research Centers and Institutes. Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive information on the NU research activities and profiles of faculty and researchers.

About Electromedical Technologies

Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company's goal is to reduce pain and improve overall human wellbeing. The Company's current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. For more information, please visit http://www.electromedtech.com. Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and currently not cleared in the US.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Corporate Contact:

Electromedical Technologies, Inc.Hanover InternationalTel: 1.888.880.7888email: ir@electromedtech.comhttps://electromedtech.com

View original content:http://www.prnewswire.com/news-releases/electromedical-technologies-and-nazarbayev-university-complete-agreement-to-expand-promising-joint-research-programs-301304872.html

SOURCE Electromedical Technologies, Inc.

Company Codes: OTC-PINK:EMED, OTC-QB:EMED, OTC-QX:EMED

Link:
Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs - BioSpace

Physiology

OpSens Awarded Innovative Technology Contract by Vizient for OptoWire III – BioSpace

Contract awarded for products that bring improvement to health care industry

QUEBEC CITY, April 7, 2021 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company, announced today it has been awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the U.S. The contract was awarded based on the recommendation of OptoWire III, a guidewire to diagnose and treat coronary disease, by hospital experts who serve on one of Vizient's member-led councils.

Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.

The OpSens OptoWire III is a modern pressure guidewire designed for contemporary clinical practice to diagnose, treat, and confirm results in coronary arteries. The OptoWire III allows navigation through complex anatomies, delivery of a stent without guidewire exchange, choices among different hyperemic and resting indices to assess coronary physiology, and confirmation of treatment with easy and reliable post-PCI measurements. The accuracy of the device, or absence of drift, and the possibility to use a single wire for the full procedure, can cut time and costs from the procedure and provides confidence in the diagnosis with consistent and repeatable measurements.

Louis Laflamme, President and Chief Executive Officer of OpSens, commented, "We are delighted to have been awarded a contract with Vizient. We are honored to be rewarded for the innovation we are bringing with the OptoWire III. Working with hospital systems has been a key initiative within OpSens and we are excited to be in the position to serve the numerous Vizient members through this contract."

"Hospitals and providers are looking for innovations that offer unique benefit over other products available on the market today. Our member council determined this technology met the criteria to be awarded with the Innovative Technology contract. Congratulations to OpSens on receiving this status," said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader.

Coronary artery disease is the blockage or narrowing (stenosis) of the arteries that supply blood to the heart muscle, often due to the buildup of fatty plaque inside the arteries, which may cause heart attacks. Several studies, such as the FAME Study, showed that when Fractional Flow Reserve (FFR) is used prior to percutaneous coronary intervention (PCI), patients' outcomes are improved with major adverse cardiac events significantly reduced.

The OptoWire III offers physicians several competitive advantages, including superior steerability, reliability in coronary physiologic assessments, and the ability to use a single guidewire for the entire procedure, saving physicians and staff costs and time. Since OptoWire's approval in 2015, more than 100,000 patients have been evaluated or treated with this system.

About OpSens Inc. (www.OpSens.com or http://www.OpSensmedical.com)

OpSens focuses mainly on coronary physiology products in interventional cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.

OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, and achievements of OpSens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

SOURCE OPSENS Inc.

Company Codes: OTC-QX:OPSSF, Toronto:OPS, OTC-PINK:OPSSF

Follow this link:
OpSens Awarded Innovative Technology Contract by Vizient for OptoWire III - BioSpace

Anatomy

‘Grey’s Anatomy’: Arizona Robbins Had a Prosthetic Leg for 141 Episodes, but Jessica Capshaw Only Wore It 1 Time – Showbiz Cheat Sheet

Greys Anatomyfans never forget the horrific plane crash in season 8 that resulted in Lexie Grey (Chyler Leigh) and Mark Sloans (Eric Dane) deaths. Although it didnt happen immediately, Arizona Robbins (Jessica Capshaw) lost her leg because of the accident.

From season 9 through season 14, when Capshaw left the series, Arizona had a prosthetic leg. Oddly enough, the actor only had to wear it one time in the 141 episodes that her character had it on.

After the plane crash in season 8,Arizonadeveloped a life-threatening infection in her leg. She was adamantly against the surgeons amputating her leg. However, when her condition worsened, Callie had to choose between saving Arizonas life or cutting off her leg. After surgery, it took Arizona a very long time to come to terms with the loss of her leg.

In season 9, episode 4, she finally agreed to go to the hospital to get fitted for a prosthetic leg. TheGreys Anatomyteam hiredA Step Ahead Prostheticsto create the realistic-looking, high-heeled transfemoral prosthesis for Arizona.

The medical lab designed and built a special prop leg with a harness for a non-amputee. It was built from a cast of Capshaws upper thigh, and the technicians used real prosthetic components to make it. The prop was covered with a silicone skin color matching Capshaws skin tones. Although the doctor fits Arizona for the leg in episode 4, she did not use the specialized prop until episode 18.

In a recentGreys Anatomyreunion on Stars in the House, Capshaw made a guest appearance. The hosts asked her the same question that many fans have asked, What was it like filming with a prosthetic leg? Her response was surprising.

So, this was a common question, Capshaw began. What was confusing was that I wasnt actually filming with a prosthetic. We only shot with a prosthetic when we shot Arizona without her pants on. I didnt film with a prosthetic very much.

RELATED: Greys Anatomy: A Calzona Reunion Is Now More Possible Than Ever BeforeWhat Is Callie (Sara Ramirez) up to Since Leaving?

Throughout the six seasons, there were only a handful of times where fans saw Capshaws prosthetic leg. Most of the time, she wasnt wearing it.

It was a green screen, she added. It was a lot of CGI. I filmed with a prosthetic once. I tied my leg behind my back and then tied a prosthetic leg on.

During the reunion show, Camilla Luddington discussed the future storyline of her character, Jo Wilson. The surgeon is thinking about switching fields into pediatrics.

Its already been teased, Luddington told the panel. But shes thinking about changing to being an OB. So thats going to be a pretty big storyline for her. Im ready for my pink scrubs. And maybe Capshaw can come back.

Youre never ready for the pink scrubs! Capshaw replied.

The actor didnt indicate whether she would come back to the show, but fans hoped she does. It would be the perfect storyline for her to make a guest appearance.

Greys AnatomySeason 17 returns on March 4, 2021, at 9 p.m. EST.

Continue reading here:
'Grey's Anatomy': Arizona Robbins Had a Prosthetic Leg for 141 Episodes, but Jessica Capshaw Only Wore It 1 Time - Showbiz Cheat Sheet

Cell Biology

Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as…

SAN FRANCISCO and SUZHOU, China, Sept. 20, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, jointly announce with Eli Lilly and Company ("Lilly", NYSE: LLY) that biomarker results from the ORIENT-11 study were released in a mini oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The ORIENT-11 primary clinical results were released during the IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium as an oral presentation and simultaneously published by the Journal of Thoracic Oncology.

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements. The National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for this indication. Biomarker data analysis revealed that the MHC-II antigen presentation pathway played a key role in immunotherapy-chemotherapy combination. Higher gene expression of this pathway was significantly associated with longer progression-free survival (HR, 0.41; 95% CI, 0.23-0.76; P=0.0041) and could potentially serve as a predictive biomarker to select patients who can benefit from this regimen.

Professor Li ZHANG, Head of Department of Internal Medicine, Sun Yat-sen University Cancer Center, the primary investigator of the ORIENT-11 trial, stated: "Sintilimab in combination with pemetrexed and platinum chemotherapy showed improved efficacy and no new safety signals in locally advanced or metastatic nonsquamous NSCLC. These results will further our understanding of the performance of this combination in certain types of patients."

Dr. Wei XU, Vice President of New Drug Biology and Translational Medicine of Innovent, stated: "We were very pleased to release these biomarker results at the ESMO Virtual Congress 2020. MHC-II antigen presentation pathway might predict clinical efficacy of immunotherapy-chemotherapy. This finding could improve our understanding of the mechanism of action of this combination and provide a scientific rationale for future selection of patients who could benefit most."

Dr. Li WANG, Senior VP of Lilly China and Head of Lilly China Drug Development and Medical Affairs Center, stated: "Biomarker exploration is very important to advance cancer immunotherapy. We are very pleased that our discovery of a potential biomarker for immunotherapy will be shared at ESMO. I would like to thank all the investigators, scientists and patients involved in the trial."

About ORIENT-11 Trial

ORIENT-11 is a randomized, double-blind, Phase 3 clinical trial evaluating the efficacy and safety of TYVYT (sintilimab injection) or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy as a first-line treatment for advanced or recurrent nonsquamous non-small cell lung cancer (nsqNSCLC) without sensitizing EGFR mutations or ALK rearrangements (ClinicalTrials.gov, NCT03607539). The primary endpoint is progression-free survival (PFS) assessed by Independent Radiographic Review Committee based on RECIST v1.1. The key secondary endpoints include overall survival (OS) and safety profile.

A total of 397 subjects have been enrolled in the ORIENT-11 trial and randomized in a 2:1 ratio to receive either TYVYT (sintilimab injection) 200mg or placebo in combination with ALIMTA (pemetrexed) and platinum chemotherapy every three weeks for up to four cycles, followed by either TYVYT (sintilimab injection) or placebo plus ALIMTA (pemetrexed) maintenance therapy. The subjects will receive treatment until radiographic disease progression, unacceptable toxicity or any other conditions that require treatment discontinuation. Conditional crossover is permitted.

About nsqNSCLC

Lung cancer is a malignancy with the highest morbidity and mortality in China. NSCLC accounts for about 80 to 85 percent of lung cancer. Approximately 70 percent of NSCLC is locally advanced or metastatic at initial diagnosis, resulting in patients with having little to no chance of radical resection. Meanwhile, even after radical surgery, patients have a high chance of recurrence and eventually die from disease progression. About 70 percent of NSCLC in China is nonsquamous subtype and 50 percent of nsqNSCLC is without sensitizing EGFR mutations or ALK rearrangements. These patients do not respond well to targeted therapy and there are limited treatment options available to them.

About TYVYT (Sintilimab Injection)

TYVYT (sintilimab injection), an innovative drug with global quality standards jointly developed in China by Innovent and Lilly, has been granted marketing approval by the NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy, and included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List (NRDL) in November 2019. In April 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with ALIMTA (pemetrexed) and platinum chemotherapy as first-line therapy in nonsquamous non-small cell lung cancer (NSCLC). In May 2020, TYVYT (sintilimab injection) monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma. In August 2020, the NMPA accepted the sNDA for TYVYT (sintilimab injection) in combination with GEMZAR (gemcitabine for injection) and platinum chemotherapy as first-line therapy in squamous NSCLC.

TYVYT (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies for TYVYT (sintilimab injection) to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Meanwhile, Innovent is conducting clinical research studies on TYVYT (sintilimab injection) worldwide.

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with three products, TYVYT (sintilimab injection), BYVASDA (bevacizumab injection) and SULINNO (adalimumab injection), on market, one asset under NDA review with priority review status, four assets in Phase 3 or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT (sintilimab injection) has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: http://www.innoventbio.com.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.com and lilly.com/newsroom.

About Innovent Biologics' strategic collaboration with Eli Lilly and Company

Innovent entered into a strategic collaboration with Lilly focused on biological medicine in March 2015 a groundbreaking partnership between a Chinese pharmaceutical company and a multinational pharmaceutical company. Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China. In October 2015, the two companies announced the extension of their existing collaboration to include co-development of three additional oncology antibodies targeting oncology indications. In August 2019, Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China. Its collaboration with Lilly indicates that Innovent has established a comprehensive level of cooperation between China's innovative pharmaceuticals sector and the international pharmaceuticals sector in fields such as R&D, CMC, clinical development and commercialization. In August, 2020, Lilly and Innovent announced a global expansion of their strategic alliance for TYVYT (sintilimab injection), and Lilly will obtain an exclusive

license for TYVYT for geographies outside of China and plans to pursue registration of TYVYT in the U.S. and other markets.

TYVYT (sintilimab injection, Innovent)

ALIMTA and GEMZAR are trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Disclaimer:

1. This indication is still under clinical trial, which hasn't been approved in China. 2. Innovent does not recommend any off-label usage.3. For medical and healthcare professional use only.

View original content:http://www.prnewswire.com/news-releases/innovent-and-lilly-release-biomarker-results-of-tyvyt-sintilimab-injection-in-combination-with-alimta-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-nonsquamous-non-small-cell-lung-cancer-at-esmo-virtual-co-301134412.html

SOURCE Innovent Biologics, Inc.

Company Codes: HongKong:1801, OTC-PINK:IVBIY

The rest is here:
Innovent and Lilly Release Biomarker Results of TYVYT (Sintilimab Injection) in Combination with ALIMTA (Pemetrexed) and Platinum Chemotherapy as...

Anatomy

This ‘Grey’s Anatomy’ Alum Shares Her Theory on Why She Was Fired From the Show – Showbiz Cheat Sheet

Greys Anatomy has seen the departure of top cast members including Sandra Oh, Patrick Dempsey, and Justin Chambers over its 16 seasons. While some of the medical drama stars are written off alive and well, others have met with some sort of untimely demise.

One Emmy Award-winning actress on the show was surprised to get her pink slip from Greys producers, but hypothesized on the potential reason for her firing.

Premiering in 2005, Greys Anatomy catapulted several of its cast members to stardom including Oh, Demspey, Katherine Heigl, and show matriarch Ellen Pompeo. Yet over the past 15 years, some of the stars have either felt the need to move on or that decision was made for them.

Four main characters on Greys each met a permanent end. George OMalley (aka 007), played by T.R. Knight, was hit by a bus saving an innocent bystander in the first episode in Season 6. A plane crash in Season 8 claimed the lives of Lexie Grey (Chyler Leigh) and Eric McSteamy Sloan (Eric Dane). And fans are still in mourning over the death of Dempseys Dr. Derek Shepherd, better known as McDreamy, due to a car accident in 2015.

Knowing the creativity Greys brings to its storylines, theres always a chance these characters will reappear in spiritual form. Other cast members who exited the show still breathing include Sara Ramirez (Callie Torres), Sarah Drew (April Kempner), Jessica Capshaw (Arizona Robbins), as well as Oh, Heigl, and Chambers.

RELATED: Which Greys Anatomy Alum Has the Highest Net Worth: Sandra Oh, Katherine Heigl, or Patrick Dempsey?

Actress, director, and dancer Debbie Allen joined Greys Anatomy behind the camera in 2010, according to Deadline. Taking the directors chair for three episodes, Allen soon served in front of the camera as well in a recurring role as Jackson Averys mom, Catherine, who developed a romance with Dr. Richard Webber (played by James Pickens, Jr.). The two wed after Webbers wife Adele (played by Loretta Devine) died from Alzheimers disease.

Named executive producer of the medical drama by showrunner Shonda Rhimes in 2015, Allen continues to juggle her many responsibilities on the prime time hit show.

With showbiz sometimes being a small world, Allen and Devine had worked together on several occasions prior to their time on Greys. Their continual reunions prompted Devine to speculate on why her character made a permanent departure.

RELATED: Greys Anatomy: James Pickens Talks Richard Webbers Diagnosis and If There Is a Future for Richard and Catherine

In a segment for PeopleTVsCouch Surfing in August 2019, Devine recalled getting written out of Greys.

I got an Emmy for this show for best guest spot and then they fired me right after that, she said, according to Entertainment Weekly. They killed me with that damn Alzheimers.

Devine had been a part of the show for two years before Allen signed on. The actress reflected on their history together and how it often seems that when Allen comes on board, Devine gets the boot.

When I was doingDreamgirls, Debbie Allen came over, took over that, then I was gone, she explained with a laugh. Then she came over there toGreys Anatomy, took over that, then I was gone. I was atThe Client Listand they said Debbie Allen was coming in to direct, I got scared as hell.

The Greys alum clearly feels no ill will toward Allen for the heightened coincidence. Debbies directed me in a million things. Ive done her plays, Devine shared. I love Debbie Allen, but the truth is the truth.

Follow this link:
This 'Grey's Anatomy' Alum Shares Her Theory on Why She Was Fired From the Show - Showbiz Cheat Sheet

Anatomy

3 ‘Grey’s Anatomy’ Deaths We Will Never Get Over – Showbiz Cheat Sheet

Lets face it, Greys Anatomy is laced with tragic deaths. It all started when Dylan Young (Kyle Chandler) aka the bomb squad guy exploded right in front of Meredith Grey (Ellen Pompeo). Then eventually, the characters nicknamed the hospital Seattle Grace Mercy Death. And now, fans are always wondering who is next. So here are some of the most memorable deaths on Greys Anatomy if you handle reliving the heartbreak.

RELATED: Greys Anatomy: Where Is George O Malley Now, and Why Did He Leave the Show?

Were not crying, youre crying. George OMalley (T.R. Knight) went out like a hero and well never forget it.

In the Greys Anatomy episode titled Now or Never, Owen Hunt (Kevin McKidd) told George he was a natural for trauma. So he decided to join the army. Of course, everyone wanted to stop the character from going. But before they were able to, a John Doe was brought in after being hit by a bus, saving a womans life in the process.

John Doe was unrecognizable and unable to speak. Then he seemingly wrote 007 on Merediths hand. Instantly realizing this was Georges nickname, Meredith and the rest of the doctors rushed to save his life.

All the while, his best friend, Izzie Stevens (Katherine Heigl), was also dying. Then in a dream sequence, Izzie went on the elevator to heaven in the pink dress she wore when Denny Duquette (Jeffrey Dean Morgan) died. Once she reached the top, George was on the other side in his U.S. Army uniform. Finally, in the next episode, the doctors confirmed George was gone and he wasnt coming back.

RELATED: Greys Anatomy Fans Still Wish Mark and Lexie Could Have Lived Happily Ever After

Lexie Grey (Chyler Leigh) and Mark Sloan (Eric Dane) died when they finally realized they were meant to be. And if thats not heartbreaking, we dont know what is.

In the Greys Anatomy Season 8 finale titled Flight Lexie, Mark, Meredith, Cristina Yang (Sandra Oh), Arizona Robbins (Jessica Capshaw), and Derek Shepherd (Patrick Dempsey) experienced a plane crash together. Then toward the start of the episode, everyone discovered Lexie was crushed by a piece of the plane.

Lexie was still alive when they found her. But realizing it was too late, Mark promised her the best life together. Then he held her hand as she died, sobbing, I love you.

In the next episode, Going, Going, Gone, Greys Anatomy revealed Mark survived long enough to make it back to Seattle Grace Mercy West. He also seemed to bounce back for a short period of time. However, Mark eventually died because of his injuries from the crash. But his friends were able to say goodbye as he was taken off life support.

RELATED: Why Greys Anatomy Hasnt Seen a Major Death for Some Time

Meredith and Dereks love story was at the center of Greys Anatomy. So when Derek died in season 11, everything changed.

In the episode called How to Save a Life, Derek was hit by a semi-truck. He wasnt brought to Grey Sloan Memorial. Rather, he went to Dillard, which was closer to the accident.

Upon arrival, Derek was rushed into surgery. Penelope Blake (Samantha Sloyan) noticed Derek needed a CT scan because of a blown pupil. However, she was dismissed by her attending because Derek was bleeding into his chest. Meanwhile, the neurosurgeon on call came in too late. So by the time the doctors at Dillard were able to do anything for the brain bleed, Derek was pronounced brain dead.

Eventually, Meredith arrived at Dillard and she had to say goodbye to her husband and the father of her children. You go, Meredith said. Well be fine. Now please excuse us as we sob for the rest of eternity.

Check outShowbiz Cheat Sheeton Facebook!

Read the original post:
3 'Grey's Anatomy' Deaths We Will Never Get Over - Showbiz Cheat Sheet

Immunology

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases – BioSpace

SAN DIEGO, May 19, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at different stages of development.

E3 ligases are an important class of proteins responsible for directing target proteins to the proteasome for degradation. Small molecules directed to novel E3 ligases with potentially differentiated properties, such as tissue-restricted bioactivity or stronger target recognition, have the potential to unlock a wide range of valuable therapeutic applications.

As part of the agreement, Vividion will be responsible for early drug discovery and pre-clinical development for selected programs. For a subset of such programs, Vividion has the right to conduct clinical development up to proof-of-concept with the option to share development costs and split U.S. profits and losses with Roche.

Vividion will receive $135 million in a cash upfront payment from Roche and is eligible to receive several billion dollars in payments based on the achievement of preclinical, development and commercial milestoness, as well as royalties on sales of commercialized products resulting from the collaboration.

"We are thrilled to partner with Roche, marking the second major collaboration for Vividion focused on developing small molecule drugs against promising, untapped therapeutic targets," stated Dr. Diego Miralles, Chief Executive Officer of Vividion. "This collaboration with Roche will further expand a new pillar of our pipeline focused on leveraging distinct E3 ligases to bring cutting-edge treatments to patients in need."

"Our proprietary platform has demonstrated the ability to identify molecules that can drug challenging protein classes, such as transcription factors, adaptor proteins, and E3 ligases," stated Dr. Fred Aslan, President and Chief Business Officer of Vividion. "We look forward to discovering new therapies with Roche while simultaneously advancing our wholly owned pipeline."

"Partnering is a cornerstone of Roche's research strategy to transform novel ideas into medicines. We are excited about Vividion's approach to small molecule discovery and are looking forward to working with their team to discover potential new medicines for patients with cancer and immunological diseases," said James Sabry, Global Head of Roche Pharma Partnering.

About Vividion Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company's cutting-edge platform was spun out of the labs of Vividion's scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. For more information, please visit http://www.vividion.com.

Contact:Nick Veomettmedia@vividion.com (858) 257-1535

View original content to download multimedia:http://www.prnewswire.com/news-releases/vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases-301061339.html

SOURCE Vividion Therapeutics

Company Codes: OTC-PINK:RHHBY, Swiss:RO, Swiss:ROG, OTC-QX:RHHBY

Link:
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases - BioSpace